Inhibitor-Directed Imaging of Prostate Cancer

前列腺癌的抑制剂导向成像

• 批准号: 7541243
• 负责人: Clifford Berkman
• 金额: $ 19.51万
• 依托单位: WASHINGTON STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-29 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7541243
• 关键词: Address; Affinity; Animal Model; Antibodies; Attention; Binding; Biodistribution; Cancer Model; Cell Surface Receptors; Cell surface; Cells; Chelating Agents; Chemicals; Chemistry; Complex; Confocal Microscopy; Contrast Media; Data; Development; Diagnostic; Disease; Dyes; Enzymes; Evaluation; Exhibits; Flow Cytometry; Fluorescence; Fluorescence Microscopy; Foundations; Glutamate Carboxypeptidase II; Goals; Image; Imaging technology; In Vitro; Label; Libraries; Link; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of prostate; Metals; Mus; Nuclear; Outcome; Property; Prostatic; Radioimmunodetection; Radioimmunotherapy; Radioisotopes; Radiology Specialty; Radionuclide Imaging; Reporter; Research; Research Personnel; Risk; Solid; Specificity; Structure; Technetium 99m; Technology; Testing; Therapeutic; Translating; Tumor-Associated Vasculature; Ursidae Family; Work; Xenograft procedure; anticancer research; base; cancer cell; cellular imaging; concept; cytotoxic; experience; in vivo; inhibitor/antagonist; innovation; member; metal complex; novel; novel diagnostics; novel therapeutics; pyrrolidin-3-yl-methanesulfonic acid; radiologist; single photon emission computed tomography; small molecule; success; tumor; uptake

DESCRIPTION (provided by applicant): The inhibition of prostate-specific membrane antigen (PSMA) by tight-binding small-molecule inhibitors has not been fully exploited for chemotherapeutic or imaging strategies. Our long-term goal is to develop novel delivery mechanisms for either cytotoxic or imaging agents that capitalize on the potency and specific affinity of tight-binding inhibitors for cell-surface hydrolytic enzymes. The overall objective of this R21 application is to prove the concept that potent inhibitors of PMSA which bear a radionuclide-chelating motif that, when bound to technetium-99m (Tc-99m), will selectively tag prostate cancer cells for SPECT (single photon emission computed tomography). Our central hypothesis for the proposed work is that small-molecule inhibitors of PSMA outfitted with a metal-chelating motif can deliver radionuclides specifically to prostate cancer cells that express PSMA. The rationale for undertaking the proposed research is that, once we demonstrate that potent small-molecule inhibitors of PSMA bearing a radionuclide can be selectively delivered to PSMA-expressing cells, it will serve as a proof-of-concept for the development of novel therapeutic and imaging technology for prostate cancer in a subsequent R01 proposal. A library of selective PSMA inhibitors possessing a metal-chelating motif will first be generated using a modular synthetic approach. When loaded with Tb(lll) or Eu(lll), the fluorescent properties of these tethered metal-chelate inhibitors will allow for in vitro evaluation of these probes by fluorescence microscopy and flow cytometry. Lastly, the chelator-tethered inhibitors will be loaded with 99Tc to selectively deliver this imaging radionuclide specifically to PSMA-expressing cancer cells. The expected positive impact of these results is that a foundation for new diagnostic strategies for prostate cancer will be established. These accomplishments are important, because these novel inhibitors of PSMA can later modified to deliver other radionuclides suitable for therapeutic applications for prostate cancer.

描述（由申请人提供）：紧密结合小分子抑制剂对前列腺特异性膜抗原（PSMA）的抑制尚未完全用于化疗或成像策略。我们的长期目标是开发新的细胞毒性或成像剂的传递机制，利用细胞表面水解酶的紧密结合抑制剂的效力和特异性亲和力。该R21申请的总体目标是证明具有放射性核素螯合基序的PMSA的有效抑制剂的概念，当与锝-99m（Tc-99 m）结合时，其将选择性地标记前列腺癌细胞用于SPECT（单光子发射计算机断层扫描）。我们提出的工作的中心假设是，PSMA的小分子抑制剂配备了金属螯合基序可以提供放射性核素特异性表达PSMA的前列腺癌细胞。进行拟议研究的基本原理是，一旦我们证明携带放射性核素的PSMA的有效小分子抑制剂可以选择性地递送到PSMA表达细胞，它将在随后的R 01提案中作为开发前列腺癌新型治疗和成像技术的概念验证。首先使用模块化合成方法生成具有金属螯合基序的选择性PSMA抑制剂的文库。当负载有Tb（III）或Eu（III）时，这些拴系的金属螯合物抑制剂的荧光性质将允许通过荧光显微术和流式细胞术对这些探针进行体外评价。最后，螯合剂栓系的抑制剂将负载99 Tc以选择性地将该成像放射性核素特异性递送至表达PSMA的癌细胞。这些结果的预期积极影响是将建立前列腺癌新诊断策略的基础。这些成就是重要的，因为这些新型PSMA抑制剂可以在以后进行修饰，以提供适用于前列腺癌治疗应用的其他放射性核素。

项目成果

In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen.

• DOI: 10.1002/pros.20909
• 发表时间: 2009-05-01
• 期刊: PROSTATE
• 影响因子: 2.8
• 作者: Liu, Tiancheng;Wu, Lisa Y.;Choi, Joseph K.;Berkman, Clifford E.
• 通讯作者: Berkman, Clifford E.

Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.

• DOI: 10.2967/jnumed.109.066589
• 发表时间: 2009-12
• 期刊: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
• 作者: Lapi SE;Wahnishe H;Pham D;Wu LY;Nedrow-Byers JR;Liu T;Vejdani K;VanBrocklin HF;Berkman CE;Jones EF
• 通讯作者: Jones EF